FindTrial
Sign In

The impact of dexmedetomidine nasal spray before surgery on postoperative myocardial injury in patients undergoing coronary artery bypass grafting

The impact of dexmedetomidine nasal spray before surgery on postoperative myocardial injury in patients undergoing coronary artery bypass grafting: A randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500111431
Enrollment
Unknown
Registered
2025-10-31
Start date
2025-11-01
Completion date
Unknown
Last updated
2025-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery sclerosis requires coronary artery bypass surgery

Interventions

Dexmedetomidine Group:30 minutes before bedtime and 30 minutes before induction of anesthesia ,dexmedetomidine will be sprayed (1 ug/kg) into the nasal cavity
Saline Group:30 minutes before bedtime and 30 minutes before induction of anesthesia ,normal saline will be sprayed into the nasal cavity

Sponsors

The Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Patients undergoing coronary artery bypass grafting on extracorporeal circulation under general anesthesia; 2.ASA class II-IV; 3.Sign the informed consent form; 4.Age 18-80 years;

Exclusion criteria

Exclusion criteria: 1.Patients who refused to sign the consent form; 2.Allergic rhinitis ,abnormal nasal structure and history of respiratory infection in the last two weeks; 3.Serious hepatic dysfunction (Child-Pugh class C) and serious renal dysfunction (undergoing dialysis before surgery); 4.Contraindications to the use of dexmedetomidine(allergic?SBP180 mmHg, DBP 100 mmHg?preoperative left ventricular ejection fraction less than 30%, sick sinus syndrome, severe sinus bradycardia (<50 beats per min [bpm]), or second-degree or greater atrioventricular block without pacemaker); 5.Preoperative cognitive impairment or mental illness; 6.Pregnant and lactating women; 7.Emergency surgery, secondary surgery;

Design outcomes

Primary

MeasureTime frame
Hyper-sensitive troponin T;—

Secondary

MeasureTime frame
Sleep quality;Ramsay Sedation Scale;Liver and kidney function;Incidence of adverse reactions such as hypotension, arrhythmia, respiratory depression, nausea, and vomiting;Mortality rate 30 days after surgery;Incidence of postoperative delirium;LVEF value;Concentrations of serum creatine kinase isoenzyme (CK-MB), lactate dehydrogenase (LDH), creatine kinase (CK), and N-terminal pro-brain natriuretic peptide (NT-proBNP);Dosage of vasoactive drugs;Mechanical ventilation duration, ICU stay duration, and hospital stay duration;—

Countries

China

Contacts

Public ContactDunyi Qi

The Affiliated Hospital of Xuzhou Medical University

Qdy6808@sina.com+86 180 5226 8338

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026